CFTR and cystic fibrosis: These CFTR modulators enhanced CFTR activation by forskolin in Ussing chamber and increased apical fluid height up to 25% of WT levels, which is considered a robust response compared to most other CF populations tested and expected to provide significant clinical benefit to patients (Table 1).